NCT07037901

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2b, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 220 (estimated)
• Sponsor: Inmagene LLC · Industry
• Sex: All
• Age: 18 Years – 74 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Detailed description

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy and safety profile of various dose regimens of IMG-007 in adult participants with moderate-to-severe active atopic dermatitis (AD) up to 52 weeks.

Conditions

• Atopic Dermatitis
• Atopic Dermatitis Eczema
• Eczema

Interventions

Type	Name	Description
DRUG	IMG-007	Participants will receive IMG-007 subcutaneously.
DRUG	Placebo	Participants will receive a placebo subcutaneously.

Timeline

• Start date: 2025-06-17
• Primary completion: 2026-11-01
• Completion: 2027-10-01
• First posted: 2025-06-26
• Last updated: 2026-02-19

Locations

23 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study